

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/575592	First Named Inventor: Kettle
371 Filing Date: April 12, 2006	Attorney Docket No.: 101250-1P US
Examiner: Mark L. Berch	Group Art Unit : 1624
Customer No.: 22466	Confirmation No.: 9563
Title: Novel Thioxanthine Derivatives for Use as Inhibitors of MPO	

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir,

Applicants submit herewith a list of patents and publications pursuant to the duty to disclose in accordance with 37 C.F.R. § 1.56.

In accordance with 37 C.F.R. § 1.97 (g) and (h), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made or that the information cited is material to patentability as defined in 37 C.F.R. § 1.56.

In accordance with the U.S. Patent Office's partial waiver of the requirement under 37 C.F.R. 1.98(a)(2)(i), only copies of any cited foreign patent documents, non-patent literature documents (excluding cited co-pending U.S. applications), English language translation(s) of non-English language foreign patent(s)/patent application publication(s), English language translation(s) of non-English language non-patent literature document(s), English language Abstracts, PCT International Search Report(s), and USPTO Office Actions cited in the accompanying PTO SB08 Form(s) are submitted herewith.

In addition, Applicant(s) wish to call to the Examiner's attention the following commonly-owned, co-pending patent application(s) and patents, and Office Action(s) issued therein:

- 1) U.S. Application No. 11/577833, Attorney Docket No. 101584-1P US, filed on April 24, 2007;
- 2) U.S. Application No. 11/720913, Attorney Docket No. 101621-1P US, filed on June 5, 2007;
and
- 3) U.S. Application No. 11/756967, Attorney Docket No. 102288-2 US, filed on June 1, 2007.

In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed before the mailing of a **first Office Action** on the merits.

It is respectfully requested that each of the patents and publications listed on the attached Form SB08, and other information contained herein, be considered by the Examiner and made of record in this application.

Although Applicants believe no fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 26-0166, referencing Attorney Docket No. 101250-1P US.

Respectfully submitted,

/Jacqueline M. Cohen/

Name: Jacqueline M. Cohen

Dated: February 11, 2008

Reg. No.: 51,574

Phone No.: 302-885-4269

Intellectual Property, Patents

AstraZeneca

1800 Concord Pike

Wilmington

DE-19850-5437